This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 241 Users Online

Enteral Feeding Formula Market

Increase in preterm deliveries and a swell in the frequency of malnutrition to boost Enteral Feeding Formula Revenue: Opportunities ahead

Global Enteral Feeding Formula Market by Product Type (Standard Formula, Disease-specific Formula)

Market Snapshot

Newly released Enteral Feeding Formula Market analysis report by Persistence Market Research shows that global sales of Enteral Feeding Formula Market in 2022 was held at US$ 6.4 Bn. With a CAGR of 7.1% during 2023 - 2033, the market is projected to reach a valuation of US$ 13.5 Bn by 2033. Standard Formula is expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 7.8% during 2023 – 2033.

Attribute

Details

Global Enteral Feeding Formula Market (2023)

US$ 6.8 Bn

Global Enteral Feeding Formula Market (2033)

US$ 13.5 Bn

Global Enteral Feeding Formula Market CAGR (2023 – 2033)

7.1%

U.S. Enteral Feeding Formula Market CAGR (2023 – 2033)

7.4%

Key Companies Profiled

  • Danone
  • Nestle Nutrition
  • Abbott Nutrition
  • Mead Johnson & Company
  • Fresenius Kabi AG
  • B. Braun Melsungen AG
  • Otsuka Holdings Co. Ltd.
  • Nutritional Medicinals, LLC
  • Kate Farms
  • Medtrition Inc.
  • Victus, Inc.
  • Global Health Products, Inc.
  • Meiji Holdings
  • Reckitt Benckiser Group
Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Revenue of Enteral Feeding Formula Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the Enteral Feeding Formula Market research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value of the Enteral Feeding Formula Market increased at around 6.7% CAGR.

Enteral nutrition, commonly known as tube feeding, refers to any feeding strategy through the gastrointestinal system to supply caloric needs, such as a regular oral meal or liquid supplements. A nasoenteral tube is inserted through the nose into the stomach, while a jejunostomy tube is inserted through the skin.

Tube feeding formula is utilized in individuals with chronic diseases such as head trauma, cancer, and stroke. Furthermore, the nutrition formula assists preterm newborns in obtaining the necessary nutrients and drugs. Enteral nutrition is indicated for patients with chronic illness conditions to counteract a weakened immune system, which affects eating patterns and results in significant weight loss.

Patients who have difficulty swallowing meals are given external nourishment through a tube. As a result, the rise in chronic illnesses such as cancer and cardiovascular disease is likely to fuel market development throughout the forecast period. Moreover, the increased prevalence of malnutrition is propelling the global enteral nutrition market forward. At the same time, increasing government efforts, investments, and funding for R&D are likely to fuel market expansion throughout the projection period.

Furthermore, factors such as investments in research and development of innovative medical nutritional products targeting various health issues, as well as financing from various nutrition industry businesses, are likely to fuel the worldwide enteral nutrition market growth throughout the forecast period.

With expanding therapeutic uses of enteral feeding formula and the launch of new technologically enhanced enteral feeding formula, demand for enteral feeding formula is booming. Furthermore, the expanding elderly population worldwide, as well as the rising occurrence of preterm births, are driving market expansion.

The need for enteral feeding formulae grows in tandem with the number of COVID-19 patients admitted to hospitals. The critical care segment of the enteral feeding formula business is rapidly increasing due to a growth in the number of COVID-19 patients, which is also pushing the consumption of nutritious feeding Formula among ventilator-dependent patients.

Increased awareness among healthcare workers about hospital-associated malnutrition is expected to increase the use of enteral feeding Formula in hospitals. Furthermore, the increased number of ICU admissions during COVID-19, as well as the rising need for enteral formulations among critically ill patients, are expected to drive market growth.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Which Factors are Propelling Enteral Feeding Formula Demand?

An aging population and a rising demand for home care primarily drive the market. The development of inexpensive and effective diabetes medication, as well as people's knowledge of diabetes self-management and government assistance, are all driving market expansion. Factors such as an increase in preterm deliveries and an increase in the frequency of malnutrition in hospitalized children are driving up demand for these formulas.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Which Factors are Impeding Enteral Feeding Formula Market Growth?

The primary constraints impeding the growth of the enteral nutrition market are the adverse effects and problems associated with enteral feedings. Aggressive enteral feeding may increase the risk of aspiration or vomiting in a kid with gastroesophageal reflux. Other physical drawbacks include diarrhea, skin breakdown, and anatomic disturbance. A dislodged or clogged feeding tube is one of the mechanical drawbacks. Furthermore, in low- and medium-income nations, a lack of understanding about healthcare, diet, and correct nutrition is a key impediment to the growth of the worldwide enteral nutrition market.

Prerna Shiv

Prerna Shiv
Client Partner

Let's Connect

Conect me to identify wining opportunities

Ask An Expert
I'm Available

Region-wise Analysis

Which Region is projected to Offer the Largest Opportunity for Enteral Feeding Formula Market?

In 2022, North America held the largest share of the global Enteral Feeding Formula market. Due to the reasons such as the expanding elderly population, the rising frequency of preterm birth, and the increasing number of chronic illness patients, North America dominates the worldwide enteral feeding formula market. Furthermore, since patients prefer home-based enteral treatment, the frequency of hospital and clinic visits has dropped. Also, rising malnutrition is predicted to drive up in the region which has been driving the market expansion.

Country-wise Analysis

U.S. Enteral Feeding Formula Market Analysis

The United States is expected to have the highest market share of US$ 3.5 Bn by the end of 2033. The market has previously grown at a considerable CAGR of 7.2% during the forecast period.

The expanding elderly population will increase the prevalence of chronic illnesses such as cancer and diabetes, resulting in a rise in patient hospitalization. Furthermore, according to the WHO, around 15 million kids are delivered prematurely, and this figure is growing. As a result, the market in the country is likely to expand throughout the forecast period.

U.K. Enteral Feeding Formula Market Analysis

The market in the U.K. is expected to reach a valuation of US$ 613 Mn by 2033, growing at a CAGR of 8.3% during 2023 – 2033. The market is projected to gross an absolute dollar opportunity of US$ 336 Mn during the forecast period.

Japan Enteral Feeding Formula Market Analysis

In Japan, the market is expected to reach a valuation of US$ 575 Mn by 2033. During the forecast period, the market in the country is expected to garner an absolute dollar opportunity of US$ 315 Mn, growing at a CAGR of 8.3%.

South Korea Enteral Feeding Formula Market Analysis

The market in South Korea is projected to grow at a CAGR of 6.9% during 2023 – 2033. During this period, the market is projected to witness an absolute dollar opportunity of US$ 143 Mn and reach US$ 292 Mn by 2033.

Category-wise Insights

Which Product Type is expected to propel the growth for Enteral Feeding Formula providers?

Standard Formula commanded the largest revenue in the enteral feeding formula market and grew at a CAGR of 7.2% during 2018-22. The market through standard formula accounted for the largest market share due to the substantial demand for enteral nutrition and basic clinical nutrition, as well as increased investment by large corporations. Polymeric formulas and monomeric formulations are subsets of standard formulae. There are various modifications of standard Formula available due to the rising need for low-cost nutritional formulations. Volume-sensitive individuals and those with congestive heart failure are particularly fond of standard tube feeds.

Which Flow Type is expected to propel maximum growth for Enteral Feeding Formula providers?

Intermittent Feeding Flow commanded the largest revenue in this regard, growing at a CAGR of nearly 6.8% during 2018-22. Because intermittent feeding has been shown to be more tolerable in patients than bolus feeding, this segment accounted for the majority of market revenue. Furthermore, because this type of feeding does not need the use of feeding pumps, it allows for more mobility in between feedings. This is projected to increase its use in both hospital and homecare settings, boosting industry development.

Competitive Analysis

Some of the key players operating in the enteral feeding formula market include Danone, Nestle Nutrition, Abbott Nutrition, Mead Johnson & Company, Fresenius Kabi AG, B. Braun Melsungen AG, Otsuka Holdings Co. Ltd., Nutritional Medicinals, LLC, Kate Farms, Medtrition Inc., Victus, Inc., Global Health Products, Inc., and Meiji Holdings.

Some of the recent developments of key Enteral Feeding Formula providers are as follows:

  • In October 2020, Nestle Health Science introduced the first ready-to-drink protein-based comprehensive nutrition Foods in China. This protein-based comprehensive nutrition food is intended for Special Medical Purposes for malnourished patients.
  • In June 2020, Hormel Foods is recognized on 3BL Media's list of the 100 Best Corporate Citizens, which recognizes excellent environmental, social, and governance (ESG) transparency and performance among the 1,000 biggest publicly traded firms in the United States. This boosts the company's credibility and builds a positive reputation in the industry.

Similarly, recent developments related to companies in the Enteral Feeding Formula market have been tracked by the team at Persistence Market Research, which are available in the full report.

Segments Covered in Enteral Feeding Formula Market Analysis

By Product Type

  • Standard Formula
  • Disease-specific Formula

By Flow Type

  • Intermittent Feeding Flow
  • Continuous Feeding Flow

By Stage

  • Adult
  • Paediatric

By Indication

  • Alzheimer’s
  • Nutrition Deficiency
  • Cancer Care
  • Diabetes
  • Chronic Kidney Diseases
  • Orphan Diseases
  • Dysphagia
  • Pain Management
  • Malabsorption/GI Disorder/Diarrhoea
  • Other Indications

By Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

- Companies Covered in This Report -

  • Danone
  • Nestle Nutrition
  • Abbott Nutrition
  • Mead Johnson & Company, LLC
  • Fresenius Kabi AG
  • Meiji Holdings Co., Ltd.
  • Victus

- Frequently Asked Questions -

The market is worth more than US$ 6.4 Bn at present.

The market value is projected to increase at a CAGR of around 6.7% during 2023 – 2033.

The market value increased at a CAGR of around 7.1% during 2018 – 2022.

The rising frequency of chronic illnesses, an increase in preterm births, and an aging population are the key factors driving growth in the industry.

The Enteral Feeding Formula Market in China is projected to expand at a CAGR of around 7.7% during 2023 – 2033.

While the market in South Korea is expected to grow at nearly 6.9%, the market in Japan is projected to register a CAGR of nearly 8.3% during 2023 - 2033.

Google translate